Martin P J
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
Exp Hematol. 1995 Feb;23(2):174-9.
One possible mechanism by which donor T cells might facilitate allogeneic marrow engraftment is through the production of lymphokines or cytokines that promote proliferation and differentiation of hematopoietic stem cells. To address this hypothesis, we have tested whether alloactivated donor T cells can accelerate initial engraftment in mice when limiting numbers of marrow cells were given to recipients in parent-->F1 strain combinations where rejection is not a limiting factor. Lethally irradiated (11 Gy) F1 recipients were transplanted with grafts composed of 1 x 10(6) T cell-depleted parental marrow cells with no T cells added or with 1 to 2 x 10(6) purified CD3+ parental or F1 lymph node cells added. Parental T cells capable of causing graft-vs.-host disease (GVHD) slowed the rate of initial engraftment, as measured by the number of nucleated cells in the marrow between 7- and 14-days posttransplantation, while F1 T cells had no effect compared to controls transplanted without T cells in the graft. Both F1 and parental T cells caused an increase in peripheral blood leukocyte counts first apparent at 2 weeks posttransplantation. Splenic erythropoiesis as measured by 59Fe incorporation was not affected by either parental or F1 T cells during the first 2 weeks posttransplantation. The slower marrow reconstitution in recipients transplanted with parental T cells may have several explanations that are not mutually exclusive. Elaboration of tumor necrosis factor (TNF), interferon-gamma (INF-gamma), or transforming growth factor-beta (TGF-beta) by activated T cells may directly inhibit hematopoiesis or may interfere with the production of another cytokine necessary for hematopoiesis. Inflammatory mediators elaborated during the initiation of GVHD may also promote early mobilization of cells from the marrow into the blood. Finally, GVHD could cause damage to the hematopoietic microenvironment.
供体T细胞促进异基因骨髓植入的一种可能机制是通过产生促进造血干细胞增殖和分化的淋巴因子或细胞因子。为了验证这一假设,我们进行了试验,在亲代→F1品系组合的小鼠中,当给予受体有限数量的骨髓细胞时(在此组合中排斥反应不是限制因素),观察同种异体激活的供体T细胞是否能加速初始植入。对接受11 Gy致死性照射的F1受体,移植由1×10⁶个去除T细胞的亲代骨髓细胞组成的移植物,不添加T细胞,或添加1至2×10⁶个纯化的亲代或F1 CD3⁺淋巴结细胞。能够引起移植物抗宿主病(GVHD)的亲代T细胞减缓了初始植入的速度,这通过移植后7至14天骨髓中有核细胞的数量来衡量,而与移植时未在移植物中添加T细胞的对照组相比,F1 T细胞没有影响。F1和亲代T细胞均导致外周血白细胞计数在移植后2周时首先明显增加。移植后前2周,通过⁵⁹Fe掺入测量的脾脏红细胞生成不受亲代或F1 T细胞的影响。移植亲代T细胞的受体中骨髓重建较慢可能有几种解释,这些解释并非相互排斥。活化的T细胞产生肿瘤坏死因子(TNF)、干扰素-γ(INF-γ)或转化生长因子-β(TGF-β)可能直接抑制造血,或可能干扰造血所需的另一种细胞因子的产生。GVHD起始过程中产生的炎症介质也可能促进细胞从骨髓早期动员到血液中。最后,GVHD可能会对造血微环境造成损害。